(0.34%) 5 117.44 points
(0.34%) 38 368 points
(0.39%) 15 990 points
(-0.97%) $83.04
(5.36%) $2.03
(0.35%) $2 355.40
(0.50%) $27.67
(4.10%) $959.95
(-0.27%) $0.932
(-0.45%) $10.98
(-0.57%) $0.796
(1.66%) $93.40
@ $22.05
発行日: 15 2月 2024 @ 05:38
リターン: -3.20%
前回のシグナル: 2月 14 - 05:50
前回のシグナル:
リターン: 4.26 %
Live Chart Being Loaded With Signals
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD)...
Stats | |
---|---|
本日の出来高 | 127 085 |
平均出来高 | 1.10M |
時価総額 | 1.81B |
EPS | $0 ( 2024-02-27 ) |
次の収益日 | ( $0 ) 2024-05-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -7.16 |
ATR14 | $0.0100 (0.05%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-07 | Metzger Michael A | Buy | 214 500 | Stock Options (Right to buy) |
2024-02-07 | Metzger Michael A | Buy | 39 000 | Common Stock |
2024-02-07 | Metzger Michael A | Buy | 107 250 | Common Stock |
2024-02-07 | Goldan Keith A. | Buy | 70 000 | Stock Options (Right to buy) |
2024-02-07 | Goldan Keith A. | Buy | 11 700 | Common Stock |
INSIDER POWER |
---|
46.03 |
Last 97 transactions |
Buy: 2 711 593 | Sell: 1 085 664 |
ボリューム 相関
Syndax Pharmaceuticals 相関
10 最も負の相関 | |
---|---|
VERX | -0.833 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Syndax Pharmaceuticals 相関 - 通貨/商品
Syndax Pharmaceuticals 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $-12 000.00 (0.00 %) |
EPS: | $-2.98 |
FY | 2023 |
収益: | $0 |
総利益: | $-12 000.00 (0.00 %) |
EPS: | $-2.98 |
FY | 2022 |
収益: | $0 |
総利益: | $-454 000 (0.00 %) |
EPS: | $-2.37 |
FY | 2021 |
収益: | $139.71M |
総利益: | $0.00 (0.00 %) |
EPS: | $0.480 |
Financial Reports:
No articles found.
Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。